Eagle’s Eye View: SUMMIT: A Look Into BMI, Adiposity, Tirzepitide and HFpFF
In this week’s View, Dr. Eagle looks at the SUMMIT trial and considers how body mass index (BMI) and central adiposity affect tirzepatide outcomes for heart failure with preserved ejection fraction (HFpEF). He then discusses bicuspid aortic valves type 0 (BAV-0) and its association with better long-term prognosis in patients with severe aortic stenosis (AS) undergoing tricuspid aortic valve replacement (TAVR). Finally, Dr. Eagle examines long-term risk of infective endocarditis and why it is significantly higher for mitral valve (MV) replacement versus repair.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Cardiac Surgery, Congenital Heart Disease and Pediatric Cardiology, Diabetes and Cardiometabolic Disease, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Aortic Surgery, Cardiac Surgery and CHD and Pediatrics, Cardiac Surgery and Heart Failure, Cardiac Surgery and VHD, Congenital Heart Disease, CHD and Pediatrics and Interventions, CHD and Pediatrics and Prevention, Acute Heart Failure, Interventions and Structural Heart Disease
Keywords: Heart Failure, Obesity, Abdominal, Intra-Abdominal Fat, Glucagon-Like Peptide-1 Receptor, Incretins, Body Mass Index, Waist-Height Ratio, Bicuspid Aortic Valve Disease, Aortic Valve, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Heart Valve Prosthesis, Heart Valve Diseases, Endocarditis, Endocarditis, Bacterial, Mitral Valve, EaglesEyeView
